# US 2025/0095776 A1 · Novel rna molecule for cancer detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0095776 A1
- Document ID: US20250095776A1
- Status: Published application
- Kind: A1
- Application number: 18/546,213
- Filed: 2023-05-09
- Published: 2025-03-20
- Earliest claimed: 2022-05-13
- Assignees: Hummingbird Diagnostics GmbH
- Applicants: Hummingbird Diagnostics GmbH
- Inventors: Bruno Steinkraus; Tobias Sikosek; Rastislav Horos
- Web page: https://patentgrep.com/patent/US20250095776A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 40/20: Supervised data analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention relates to a method of diagnosing cancer in a patient. Further, the present invention relates to a method of monitoring the course of cancer in a patient. Furthermore, the present invention relates to a method of determining whether a patient responds to a therapeutic treatment of cancer. The present invention also relates to a method of determining the risk for a relapse of cancer in a patient. In addition, the present invention relates to a method of detecting a minimal residual disease in a patient having cancer. Moreover, the present invention relates to a kit for carrying out these methods.

## Claims

### Claim 1

A method of
(i) diagnosing lung cancer in a patient,
(ii) monitoring the course of lung cancer in a patient,
(iii) determining whether a patient responds to a therapeutic treatment of lung cancer,
(iv) determining the risk for a relapse of lung cancer in a patient, or
(v) detecting a minimal residual disease in a patient having lung cancer
comprising the step of:
determining the level of an RNA molecule in a blood sample from a patient, wherein the RNA molecule comprises a nucleotide sequence according to SEQ ID NO: 1, is a fragment thereof, or has a sequence having at least 80% sequence identity thereto.

### Claim 2 (depends on 1)

The method of claim 1 (i), wherein the level of the RNA molecule is compared to a reference level of said RNA molecule.

### Claim 3 (depends on 2)

The method of claim 2, wherein the reference level is the level of the RNA molecule determined empirically by measuring a number of reference blood samples from
healthy subjects, and/or
subjects having lung cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein
the reference level is the level of the RNA molecule determined empirically by measuring a number of reference blood samples from healthy subjects, and wherein the level of the RNA molecule above the reference level indicates that the patient suffers from hung cancer, and/or
the reference level is the level of the RNA molecule determined empirically by measuring a number of reference blood samples from subjects having lung cancer, and wherein the level of the RNA molecule comparable with the reference level indicates that the patient suffers from lung cancer.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1 (ii), wherein said monitoring comprises determining the level of the RNA molecule in a blood sample obtained from a patient at a first point in time and in at least one further blood sample obtained from the (same) patient at a later point in time and comparing said levels determined at the different time points.

### Claim 9 (depends on 8)

The method of claim 8, wherein the level of the RNA molecule which
(i) increases over time indicates that the patient has developed lung cancer or that lung cancer is worsening in the patient,
(ii) does not change over time indicates that the patient is stable or that lung cancer is not progressing in the patient, or
(iii) decreases over time indicates that lung cancer is improving in the patient.

### Claim 10 (depends on 9)

The method of claim 9, wherein
(i) the patient was healthy at the first point in time and the level which increases over time indicates that the patient has developed lung cancer,
(ii) the patient had lung cancer at the first point in time and the level which increases over time indicates that lung cancer is worsening in the patient,
(iii) the patient had lung cancer at the first point in time and the level which does not change over time indicates that lung cancer is not progressing in the patient, or
(iv) the patient had lung cancer at the first point in time and the level which decreases over time indicates that lung cancer is improving in the patient.

### Claim at position 9

11-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1 (iii), wherein the patient is a patient to whom at least once
a drug to be used in said therapeutic treatment, and/or
another form of therapeutic treatment
is administered, has been administered, or had been administered.

### Claim 16 (depends on 15)

The method of claim 15, wherein the blood sample is isolated from the patient after at least the first administration of
said drug, and/or
another form of therapeutic treatment.

### Claim 17 (depends on 1)

The method of claim 1 (iii), wherein the level of the RNA molecule is compared to a reference level of said RNA molecule.

### Claim 18 (depends on 17)

The method of claim 17, wherein the reference level is the level of the RNA molecule determined empirically by measuring a number of reference blood samples from subjects having lung cancer.

### Claim 19 (depends on 17)

The method of claim 17, wherein the reference level is the level determined in a reference blood sample isolated from the (same) patient prior to the administration of
said drug, and/or
another form of therapeutic treatment.

### Claim 20 (depends on 17)

The method of claim 17, wherein
the level of the RNA molecule below the reference level indicates that the patient responds to said treatment of lung cancer,
the level of the RNA molecule comparable with the reference level indicates that the patient does not respond to said treatment of lung cancer, or
the level of the RNA molecule above the reference level indicates that the patient does not respond to said treatment of lung cancer.

### Claim at position 16

21-32. (canceled)

### Claim 33 (depends on 1)

The method of claim 1 (iv), wherein the determining comprises determining the level of the RNA molecule in a blood sample obtained from a patient at a first point in time after therapeutic treatment of lung cancer and in at least one further blood sample obtained from the (same) patient at a later point in time and comparing said levels determined at the different time points.

### Claim 34 (depends on 33)

The method of claim 33, wherein the level of the RNA molecule which increases over time indicates a risk of the patient for a relapse of lung cancer.

### Claim at position 19

35-44. (canceled)

### Claim 45 (depends on 1)

The method of claim 1 (v), wherein the determining comprises determining the level of the RNA molecule in a blood sample obtained from a patient at a first point in time before therapeutic treatment of lung cancer and in at least one further blood sample obtained from the (same) patient at a later point in time after therapeutic treatment and comparing said levels determined at the different time points.

### Claim 46 (depends on 45)

The method of claim 45, wherein the level of the RNA molecule which is stable over time or does not decrease over time up to/under a threshold level (representing the minimal level of the RNA molecule achievable by the therapeutic treatment of lung cancer) indicates that the patient suffers from a minimal residual disease.

### Claim 47 (depends on 46)

The method of claim 46, wherein the patient suffering from a minimal residual disease is assigned to/eligible for adjuvant therapy.

### Claim at position 23

48-56. (canceled)

### Claim 57 (depends on 1)

The method of claim 1, wherein the blood sample is whole blood or a blood fraction.

### Claim at position 25

-60. (canceled)

### Claim 61

A kit for diagnosing lung cancer in a patient, monitoring the course of lung cancer in a patient, determining whether a patient responds to a therapeutic treatment of lung cancer, determining the risk for a relapse of lung cancer in a patient, and/or detecting a minimal residual disease in a patient having lung cancer, wherein said kit comprises:
means for determining the level of an RNA molecule in a blood sample from a patient, wherein the RNA molecule comprises a nucleotide sequence according to SEQ ID NO: 1, is a fragment thereof, or has a sequence having at least 80% sequence identity thereto.

### Claim at position 27

62-63. (canceled)
